

**Supplementary Table S1.** The MAFs of the non-HLA SNPs that demonstrated significant associations with the efficacy and safety of olokizumab.

Gene	SNP	Genotype	MAF Total GnomAD	MAF European (Non-Finnish)
<i>TNFRSF1A</i>	rs767455	T/C	0.399	-
<i>TNFRSF1A</i>	rs1800692	A/G	0.291	0.227
<i>TNFAIP3</i>	rs6920220	G/A	0.158	0.208
<i>DHODH</i>	rs3213422	A/C	0.446	0.507
<i>FPGS</i>	rs10987742	C/T	0.242	0.231
<i>AMPD1</i>	rs17602729	G/A	0.086	0.129
<i>ABCC1</i>	rs3784864	A/A	0.404	0.517
<i>ABCB1</i>	rs2032582	A/C	0.539	0.549
<i>ABCB1</i>	rs1045642	A/G	0.439	-
<i>TLR5</i>	rs5744174	A/G	0.385	0.437
<i>GLCC1</i>	rs37972	T/C	0.362	-
<i>CCR6</i>	rs3093024	A/G	0.389	0.294
<i>PADI4</i>	rs874881	G/C	0.478	-
<i>PADI4</i>	rs2240336	C/T	0.428	0.402
<i>PADI4</i>	rs2301888	G/A	0.317	0.347
<i>PADI4</i>	rs2240335	C/A	0.389	0.349
<i>PADI4</i>	rs2240340	T/C	0.455	-
<i>PADI4</i>	rs11203366	G/A	0.449	-
<i>PADI4</i>	rs1748032	C/T	0.632	0.649
<i>PADI4</i>	rs11203367	C/T	0.441	-
<i>IL23R</i>	rs1884444	G/T	0.486	-
<i>IL23R</i>	rs7539625	G/A	0.326	-
<i>IL17A</i>	rs1974226	C/T	0.153	0.18
<i>IL18</i>	rs360722	A/G	0.183	0.173
<i>IL18</i>	rs360718	A/C	0.258	-
<i>IL6R</i>	rs2228145	A/C	0.379	0.396
<i>IL2RA</i>	rs2104286	T/C	0.179	-
<i>IL2RB</i>	rs3218253	G/A	0.218	0.268
<i>IL1RN</i>	rs419598	T/C	0.256	0.273
<i>IL1B</i>	rs1143634	G/A	0.192	0.241
<i>IL1B</i>	rs16944	G/A	0.421	0.332
<i>IL1B</i>	rs1143623	C/G	0.240	-